Haploidentical Stem Cell Transplantation Utilizing T-Cell Depletion as Therapy for Patients With Refractory Hematological Malignancies
Secondary objectives for this protocol are to 1) assess the kinetics of lymphohematopoietic
reconstitution and 2) describe the short and long-term (up to 5 years post- transplant)
toxicity of haploidentical stem cell transplantation, including GVHD, in children with
refractory hematological malignancies.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To ask in terms of one-year survival the efficacy of haploidentical stem cell transplantation in children with refractory hematological malignancies.
Gregory Hale, M.D.
St. Jude Children's Research Hospital
United States: Food and Drug Administration
|St. Jude Children's Research Hospital||Memphis, Tennessee 38105-2794|